EcoDrugPlus

Mdm2 Proto-Oncogene

Ensembl ID : ENSBMSG00010016662
Gene Symbol: MDM2
1 Cross references
257 Possible Orthologues:

Met Proto-Oncogene, Receptor Tyrosine Kinase

Ensembl ID : ENSBMSG00010007360
Gene Symbol: MET
1 Cross references
207 Possible Orthologues:

Mpl Proto-Oncogene, Thrombopoietin Receptor

Ensembl ID : ENSBMSG00010010732
Gene Symbol: MPL
1 Cross references
186 Possible Orthologues:

Mtor Associated Protein, Lst8 Homolog

Ensembl ID : ENSBMSG00010011822
Gene Symbol: MLST8
1 Cross references
202 Possible Orthologues:

Nad(P)h Quinone Dehydrogenase 1

Ensembl ID : ENSBMSG00010014717
Gene Symbol: NQO1
1 Cross references
195 Possible Orthologues:

Nadph Oxidase 4

Ensembl ID : ENSBMSG00010000676
Gene Symbol: NOX4
1 Cross references
150 Possible Orthologues:

Nfe2 Like Bzip Transcription Factor 2

Ensembl ID : ENSBMSG00010006157
Gene Symbol: NFE2L2
1 Cross references
216 Possible Orthologues:

Npc1 Like Intracellular Cholesterol Transporter 1

Ensembl ID : ENSBMSG00010010957
Gene Symbol: NPC1L1
1 Cross references
190 Possible Orthologues:

Pim-2 Proto-Oncogene, Serine/threonine Kinase

Ensembl ID : ENSBMSG00010014679
Gene Symbol: PIM2
1 Cross references
115 Possible Orthologues:

Pim-3 Proto-Oncogene, Serine/threonine Kinase

Ensembl ID : ENSBMSG00010019059
Gene Symbol: PIM3
1 Cross references
196 Possible Orthologues:

Rar Related Orphan Receptor C

Ensembl ID : ENSBMSG00010018612
Gene Symbol: RORC
1 Cross references
383 Possible Orthologues:

Rela Proto-Oncogene, Nf-Kb Subunit

Ensembl ID : ENSBMSG00010009559
Gene Symbol: RELA
1 Cross references
200 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).